The size of subconjunctival preparation does not influence the outcome of trabeculectomy with mitomycin C.
Wasielica-Poslednik Joanna, Hoffmann Esther M, Herzog Daniel, Aliyeva Shakhsanam, Lamparter Julia, Pfeiffer Norbert
AI Summary
This study found that trabeculectomy outcomes with MMC are similar regardless of subconjunctival preparation size, suggesting this factor alone doesn't significantly impact success or complications.
Abstract
Purpose
To compare the outcome of fornix-based trabeculectomy with mitomycin C (MMC) using 2 different sizes of subconjunctival preparation (36 mm² compared with 72 mm²).
Methods
Prospective, randomized interventional case series.
Study population: Patients 18 to 85 years of age with open-angle glaucoma and progressive visual field defects under maximum tolerated medical therapy were randomized to undergo initial fornix-based trabeculectomy with MMC (0.2 mg/mL for 5 min) with subconjunctival preparation of 6×6 mm (group A) or 8×9 mm (group B). Main outcome parameters were: intraocular pressure (IOP), best-corrected visual acuity (BCVA), number of 5-fluorouracil (5-FU) injections, and laser suturolyses (SL).
Results
Twenty-eight eyes of 26 patients were enrolled, including 14 eyes in group A and 14 in group B. At 12 months, IOP (mean±SD) was 9.69±2.5 mm Hg in group A and 9.93±3.2 mm Hg in group B (P=0.17) without glaucoma medication. Mean BCVA (logMAR) at month 12 was 0.29±0.26 in group A and 0.26±0.2 in group B (P=0.71). Patients required 3.0 5-FU in group A and 4.1±2.9 5-FU in group B (P=0.16); 1.3±1.1 SL and 1.8±1.1 SL, respectively (P=0.23). We noted 2 cases of intraocular hypotony in the 6×6 mm group (14.3%) and 1 in the 8×9 mm group (7.1%).
Conclusions
There were no significant differences between study groups in mean IOP reduction, change in BCVA, or number of applied 5-FU and SL at 1-year follow-up. The area of subconjunctival preparation is only one of several factors playing a role in the outcome of trabeculectomy with MMC.
MeSH Terms
Shields Classification
Key Concepts5
At 12 months, the mean intraocular pressure (IOP) was 9.69±2.5 mm Hg in eyes undergoing fornix-based trabeculectomy with mitomycin C (MMC) using a 6x6 mm subconjunctival preparation (group A) and 9.93±3.2 mm Hg in eyes using an 8x9 mm subconjunctival preparation (group B) (P=0.17) without glaucoma medication.
At 12 months, the mean best-corrected visual acuity (BCVA) (logMAR) was 0.29±0.26 in eyes undergoing fornix-based trabeculectomy with mitomycin C (MMC) using a 6x6 mm subconjunctival preparation (group A) and 0.26±0.2 in eyes using an 8x9 mm subconjunctival preparation (group B) (P=0.71).
Patients undergoing fornix-based trabeculectomy with mitomycin C (MMC) using a 6x6 mm subconjunctival preparation (group A) required 3.0 5-fluorouracil (5-FU) injections, and those using an 8x9 mm subconjunctival preparation (group B) required 4.1±2.9 5-FU injections (P=0.16).
Patients undergoing fornix-based trabeculectomy with mitomycin C (MMC) using a 6x6 mm subconjunctival preparation (group A) required 1.3±1.1 laser suturolyses (SL), and those using an 8x9 mm subconjunctival preparation (group B) required 1.8±1.1 SL (P=0.23).
Intraocular hypotony was noted in 2 cases (14.3%) in the 6x6 mm subconjunctival preparation group (group A) and 1 case (7.1%) in the 8x9 mm subconjunctival preparation group (group B) following fornix-based trabeculectomy with mitomycin C (MMC).
Related Articles5
Efficacy and complications of microcatheter-assisted minimally invasive glaucoma surgery for open-angle glaucoma: A systematic review and network meta-analysis.
Systematic ReviewEfficacy of Filtration Surgery and Risk Factors for Central Visual Field Deterioration in Highly Myopic Eyes With Open Angle Glaucoma.
Cohort StudyEfficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for primary open-angle glaucoma: A randomized controlled trial.
Randomized Controlled TrialOne-Year Outcomes of Preserflo Microshunt for Primary Open Angle Glaucoma: A Systematic Review and Meta-Analysis.
Systematic ReviewFive-year follow-up with the PreserFlo MicroShunt for open-angle glaucoma.
Case SeriesIs this article assigned to the wrong chapter(s)? Let us know.